Struma Ovarii

Comprehensive Guide to Struma Ovarii: Clinical Pathophysiology and Management

Struma ovarii is a rare, specialized form of ovarian teratoma that represents a significant intersection between gynecology, endocrinology, and oncology. Defined as a monodermal teratoma composed predominantly of thyroid tissue, it serves as a classic clinical example of ectopic endocrine function. While the majority of these lesions are benign, their potential for malignancy and the systemic effects of thyroid hormone production mandate a nuanced diagnostic and therapeutic approach.

This guide provides an exhaustive clinical overview for medical professionals, detailing the etiology, diagnostic pathways, and management strategies for this rare clinical entity.

1. Clinical Definition and Overview

Struma ovarii is classified as a specialized ovarian teratoma. By definition, to qualify as struma ovarii, thyroid tissue must comprise more than 50% of the overall mass of the tumor.

• Epidemiology: It accounts for approximately 0.5% to 1% of all ovarian tumors and 2.7% to 5% of ovarian teratomas.
• Demographics: While it can occur at any age, it is most frequently diagnosed in women between the ages of 40 and 60.
• Anatomic Location: It is almost exclusively unilateral, with the right ovary being involved slightly more frequently than the left.

While the World Health Organization (WHO) classifies these under germ cell tumors, their clinical behavior is distinct, often mimicking thyroid pathologies found in the cervical region, such as goiter, adenoma, or even papillary thyroid carcinoma.

2. Pathophysiology and Mechanisms

The development of struma ovarii is rooted in the pluripotentiality of germ cells within the ovary.

Etiology and Embryogenesis

The mechanism of formation is theorized through the parthenogenetic development of an ovum. Unlike typical mature cystic teratomas (dermoid cysts) which contain tissues from all three germ layers (ectoderm, mesoderm, endoderm), struma ovarii represents a monodermal differentiation where thyroid tissue dominates.

Endocrine Functionality

Only a small subset of patients (approximately 5% to 8%) with struma ovarii exhibit clinical hyperthyroidism (thyrotoxicosis). The pathophysiology involves:
1. Autonomous Production: The ectopic thyroid tissue functions independently of the hypothalamic-pituitary-thyroid axis.
2. Hormonal Overload: The tumor secretes excessive amounts of T3 and T4, which suppresses endogenous Thyroid Stimulating Hormone (TSH) production from the pituitary gland.
3. Metabolic Impact: Patients present with classic signs of hyperthyroidism, including tachycardia, weight loss, heat intolerance, and anxiety, despite having a normal-appearing cervical thyroid gland.

3. Clinical Presentation and Diagnostic Evaluation

Standard Clinical Presentation

Most patients are asymptomatic, and the tumor is often discovered incidentally during pelvic imaging or surgery for other indications. When symptomatic, presentations include:
* Abdominal/Pelvic Mass: Pelvic pain, distension, or pressure symptoms.
* Ascites: In rare cases, Meigs’ syndrome (ascites and pleural effusion) may occur, which can misleadingly suggest ovarian malignancy.
* Thyrotoxicosis: Symptomatic hyperthyroidism in a subset of cases.

Differential Diagnosis

Clinicians must distinguish struma ovarii from other adnexal pathologies:
* Mature cystic teratoma (non-struma).
* Ovarian epithelial malignancies (e.g., serous or mucinous carcinoma).
* Metastatic tumors to the ovary (Krukenberg tumor).
* Primary ovarian carcinoma.

Key Diagnostic Tests

4. Pathological Staging and Malignancy

While most cases are benign, malignant transformation (malignant struma ovarii) occurs in approximately 5% to 10% of cases.

Grading Criteria

Malignancy is diagnosed based on criteria similar to those used for thyroid cancer in the neck:
1. Papillary Carcinoma: The most common form of malignant struma ovarii.
2. Follicular Carcinoma: Less common, diagnosed by evidence of capsular or vascular invasion.
3. Metastasis: Malignant struma ovarii can metastasize to the peritoneum, liver, or lungs, necessitating an oncologic approach.

5. Clinical Indications and Management

Management is highly dependent on the size of the tumor, the age of the patient, and whether malignancy is suspected.

Surgical Intervention

• Conservative Surgery: In younger patients desiring future fertility, cystectomy or unilateral oophorectomy is the standard approach, provided the contralateral ovary is normal and there is no evidence of malignancy.
• Radical Surgery: In post-menopausal patients or those with suspicion of malignancy, total hysterectomy with bilateral salpingo-oophorectomy (THBSO) is recommended.

Adjuvant Therapy

In cases of malignant struma ovarii, management often involves a multidisciplinary team (Gynecologic Oncology and Endocrinology):
* Thyroidectomy: Occasionally performed to facilitate radioiodine therapy.
* Radioactive Iodine (I-131): Highly effective for treating residual disease or distant metastases, as the ectopic thyroid tissue avidly takes up iodine.
* Thyroid Hormone Suppression: Levothyroxine therapy to suppress TSH, thereby reducing stimulation of residual thyroid tissue.

6. Risks, Contraindications, and Long-Term Prognosis

Potential Risks

• Thyroid Storm: Rare but potentially fatal complication if the patient undergoes surgery without prior stabilization of hyperthyroidism.
• Peritoneal Spread: Malignant struma ovarii can spread throughout the peritoneum, mimicking stage III ovarian cancer.
• Surgical Complications: Risks include adhesion formation, bowel injury, or secondary infertility if bilateral oophorectomy is required.

Long-Term Prognosis

The prognosis for benign struma ovarii is excellent following surgical excision. For malignant cases, the prognosis is generally favorable compared to other ovarian malignancies, but long-term surveillance is mandatory. Patients should be monitored via:
* Serial serum thyroglobulin levels.
* Regular pelvic imaging.
* Periodic whole-body radioiodine scans if malignancy was present.

7. Frequently Asked Questions (FAQ)

1. Is struma ovarii always cancerous?

No. The vast majority of cases (over 90%) are benign. Malignant struma ovarii is rare and typically follows the behavior of well-differentiated thyroid cancer.

2. Can I get pregnant after a diagnosis of struma ovarii?

Yes. If the tumor is benign and treated with a unilateral oophorectomy, fertility is typically preserved.

3. How do doctors know if the tumor is producing thyroid hormone?

Through serum laboratory testing (TSH, free T4, and T3). If the tumor is functional, TSH will be suppressed, and T4/T3 levels will be elevated.

4. Why does an ovarian tumor cause symptoms of thyroid disease?

Because the tumor contains functional thyroid tissue that releases hormones directly into the systemic circulation, bypassing the body's natural regulatory feedback loops.

5. What is the role of the thyroid gland in the neck during diagnosis?

The cervical thyroid gland is usually normal. In fact, if the ovarian tumor is overproducing hormones, the cervical thyroid will often be inactive (atrophied) due to the suppression of TSH.

6. Is radioactive iodine used for all patients?

No. Radioactive iodine is reserved specifically for cases of malignant struma ovarii or cases where there is evidence of metastatic disease.

7. Does struma ovarii recur?

Benign struma ovarii has a low recurrence rate following complete resection. Malignant struma ovarii has a higher risk of recurrence and requires long-term surveillance.

8. Can it be misdiagnosed as ovarian cancer?

Yes. Because it can present with ascites and pelvic masses, it is often mistaken for advanced-stage ovarian epithelial carcinoma until the pathology report confirms thyroid tissue.

9. What is the standard follow-up protocol?

Follow-up usually involves annual physical exams, monitoring of thyroglobulin levels, and imaging (ultrasound or MRI) to ensure no recurrence.

10. Are there specific genetic markers for struma ovarii?

Recent research has identified mutations in the NRAS, BRAF, and HRAS genes in malignant cases, similar to those found in primary thyroid carcinomas, which may eventually guide targeted therapies.

Conclusion

Struma ovarii remains a fascinating, albeit rare, diagnostic challenge. Its management requires a collaborative approach between the gynecologic surgeon and the endocrinologist. By understanding the distinct endocrine properties of the tumor and the specific pathological criteria for malignancy, clinicians can provide effective, fertility-sparing, and life-saving care for their patients. As diagnostic imaging and molecular testing continue to evolve, the management of this condition will likely become even more personalized and precise.

Disclaimer: This guide is intended for educational and professional informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.